Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue 5, 2003, Pages 482-486

  Aletaha, D ^a   Kapral, T ^a   Smolen, J S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; ASPARTATE AMINOTRANSFERASE; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN A; GOLD DERIVATIVE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ARTICLE; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG WITHDRAWAL; DYSURIA; ECZEMA; ERYTHEMA; ERYTHROPENIA; FATIGUE; FEVER; FLUSHING; HEALTH VISITOR; HEMATOLOGIC DISEASE; HEMATOMA; HUMAN; KERATOPATHY; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD; MEDICAL SPECIALIST; MENTAL DISEASE; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; OPHTHALMOLOGY; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; RETINOPATHY; RHEUMATOID ARTHRITIS; SKIN EDEMA; SLEEP DISORDER; STOMATITIS; SWEATING; TASTE DISORDER; URINARY TRACT INFECTION; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT REDUCTION; ADULT; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0037404908     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.5.482     Document Type: Article

References (23)

1. Pinals RS. Survival in rheumatoid arthritis. Arthritis Rheum 1987;30:473-5.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32:28-37.
4. Cush JJ, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990;33:19-28.
5. McConkey B, Crockson RA, Crockson AP, Wilkinson AR. The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis. Q J Med 1973;42:785-91.
6. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
7. Weinblatt M. Treatment of rheumatoid arthritis. In: Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001:1245-58.
8. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
9. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl 1996;44:102-6.
10. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
11. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
12. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
13. Gazarian M, Tugwell P, Boers M, Bombardier C, Brooks P, Day R, et al. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology. J Rheumatol 1999;26:207-9.
14. Blyth C, Lane C. Hydroxychloroquine retinopathy: is screening necessary? BMJ 1998;316:716-17.
15. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56:188-90.
16. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
17. Singh G, Fries JF. Can liver test abnormalities in patients with rheumatoid arthritis be predicted by clinical symptoms? J Rheumatol 1992;19:1158-9.
18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
20. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74.
21. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
22. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
23. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.